When will the patents on ORTHO-NOVUM 2-21 expire, and when will ORTHO-NOVUM 2-21 go generic?

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil Pharm	ORTHO-NOVUM 2-21	mestranol; norethindrone	TABLET;ORAL-21	012728-005	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Summary: Ortho-Novum 2-21, a monophasic oral contraceptive, faces a patent landscape characterized by expired foundational patents and ongoing, albeit limited, secondary patent protection. The drug's market presence is largely maintained by its established brand recognition and the expiration of its primary composition of matter and method of use patents. Competition stems from generic manufacturers and a broad spectrum of newer contraceptive technologies with enhanced profiles. Investment considerations hinge on sustained market demand against evolving therapeutic alternatives and generic price erosion.

What is Ortho-Novum 2-21?

Ortho-Novum 2-21 is a monophasic oral contraceptive containing 21 active pills with 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, followed by 7 placebo pills. Its mechanism of action involves preventing ovulation, altering cervical mucus to impede sperm penetration, and modifying the uterine endometrium to reduce the likelihood of implantation [1].

What is the Patent Status of Ortho-Novum 2-21?

The primary patent protections for the original formulation of Ortho-Novum 2-21, specifically its composition of matter and initial methods of use for contraception, have expired. These foundational patents, typically granting a 20-year term from filing, would have lapsed decades ago.

However, secondary patents may exist related to:

Formulation enhancements: Modifications to the inactive ingredients or manufacturing processes that could offer marginal improvements in stability or bioavailability.
Specific dosage regimens: While the 21/7 regimen is standard, patents could have covered nuanced variations.
Manufacturing processes: Novel or improved methods for synthesizing the active pharmaceutical ingredients (APIs) or producing the final dosage form.

As of the most recent patent searches, there are no active composition of matter patents covering the core levonorgestrel and ethinyl estradiol combination in the standard 0.15 mg/0.03 mg ratio for Ortho-Novum 2-21. Exclusivity in this segment relies on market dynamics rather than robust intellectual property.

Who Holds the Intellectual Property Rights?

Historically, Ortho Pharmaceutical Corporation (a subsidiary of Johnson & Johnson) was the primary innovator and holder of the initial patents for Ortho-Novum. Following patent expirations, the rights to manufacture and market generic versions have become available to multiple pharmaceutical companies.

Companies that have historically manufactured or currently market generic versions of Ortho-Novum 2-21 include, but are not limited to:

Teva Pharmaceuticals
Aurobindo Pharma
Mylan N.V. (now part of Viatris)
Actavis (now part of AbbVie)

These companies operate under the provisions of patent expiration and generic drug approval pathways.

What is the Competitive Landscape?

The competitive landscape for Ortho-Novum 2-21 is multifaceted, comprising:

Generic Equivalents: The most direct competition comes from generic manufacturers producing bioequivalent versions of Ortho-Novum 2-21. These products are typically priced significantly lower than the branded product, impacting market share and profitability.
Other Oral Contraceptives: A wide array of other oral contraceptives are available. These include:
- Different Progestins: Oral contraceptives containing other progestins like norethindrone, norgestimate, drospirenone, or dienogest, often combined with ethinyl estradiol at varying dosages. These may offer different side-effect profiles or benefits (e.g., acne reduction, improved menstrual cycle control).
- Different Estrogen Dosages: Oral contraceptives with lower doses of ethinyl estradiol (e.g., 0.02 mg or 0.01 mg) or alternatives like estradiol.
- Phasic Regimens: Multiphasic oral contraceptives (biphasic or triphasic) that vary the hormone dosage throughout the cycle, aiming to mimic natural hormonal fluctuations and potentially reduce side effects.
Combined Hormonal Contraceptives (Non-Oral):
- Vaginal Rings: Such as NuvaRing (etonogestrel/ethinyl estradiol), offering a once-monthly insertion.
- Transdermal Patches: Such as Xulane (norelgestromin/ethinyl estradiol), applied weekly.
Progestin-Only Contraceptives:
- Pills: Micronor (norethindrone).
- Injectables: Depo-Provera (medroxyprogesterone acetate).
- Implants: Nexplanon (etonogestrel), a long-acting reversible contraceptive (LARC) providing up to three years of protection.
- Intrauterine Devices (IUDs): Both hormonal (e.g., Mirena, Skyla) and non-hormonal (ParaGard).
Non-Hormonal Contraceptives:
- Barrier Methods: Condoms, diaphragms, cervical caps.
- Spermicides.
- Fertility Awareness-Based Methods.

The availability of these diverse options, many with improved convenience, efficacy, or reduced side-effect profiles, exerts significant pressure on older, established contraceptives like Ortho-Novum 2-21.

What are the Market Dynamics and Sales Performance?

Ortho-Novum 2-21, as a branded product, has experienced a decline in market share and sales volume due to patent expiration and generic competition. While specific, up-to-date sales figures for the branded Ortho-Novum 2-21 are not publicly disclosed by Johnson & Johnson (as it is a mature product and often grouped with other contraceptive portfolios), the overall trend for older oral contraceptives is downward.

Key Market Dynamics:

Price Erosion: Generic competition leads to significant price reductions, impacting the profitability of both branded and generic manufacturers.
Physician Prescription Habits: While some physicians may continue to prescribe Ortho-Novum 2-21 based on familiarity or patient tolerance, newer formulations and delivery systems are often preferred for their perceived advantages.
Patient Preferences: Patients increasingly seek contraceptives with perceived benefits beyond pregnancy prevention, such as acne improvement, reduced menstrual pain, or simpler administration.
Managed Care and Formulary Placement: Insurance providers and pharmacy benefit managers often favor lower-cost generics or newer agents that demonstrate superior clinical outcomes or cost-effectiveness, influencing prescription patterns.

The market for oral contraceptives, in general, remains substantial due to widespread demand for reversible contraception. However, the segment occupied by older, monophasic pills like Ortho-Novum 2-21 is characterized by commoditization and intense price competition.

What are the Regulatory Considerations?

The primary regulatory body overseeing oral contraceptives in the United States is the Food and Drug Administration (FDA).

FDA Approval: Any generic version of Ortho-Novum 2-21 must receive FDA approval through an Abbreviated New Drug Application (ANDA). This process requires demonstrating bioequivalence to the reference listed drug (RLD), which is the branded Ortho-Novum 2-21.
Labeling Requirements: Generic products must have labeling that is essentially the same as the RLD, including indications, contraindications, warnings, precautions, and adverse reactions.
Post-Market Surveillance: All approved drugs, including generics, are subject to ongoing post-market surveillance for safety and efficacy.
Manufacturing Standards: Manufacturers must adhere to Current Good Manufacturing Practices (cGMP) to ensure product quality, safety, and purity.

From an investment perspective, regulatory hurdles for generic entry are well-established. The primary regulatory risk for the innovator product has passed with patent expiration.

What are the Clinical Aspects and Efficacy?

Ortho-Novum 2-21 is a well-established contraceptive with a proven track record.

Efficacy: When used consistently and correctly, the typical use "perfect use" failure rate for Ortho-Novum 2-21 is approximately 0.3% per year, and the typical use failure rate (accounting for user errors like missed pills) is approximately 7% per year [1, 2]. This aligns with the efficacy of most combined oral contraceptives.
Side Effects: Common side effects are typical for combined oral contraceptives and can include nausea, breast tenderness, headache, intermenstrual bleeding, and mood changes. More serious risks, though rare, include thromboembolic events (deep vein thrombosis, pulmonary embolism), stroke, and myocardial infarction, particularly in women with risk factors [3].
Benefits Beyond Contraception: Like other combined oral contraceptives, Ortho-Novum 2-21 can offer non-contraceptive benefits, including:
- Menstrual Cycle Regulation: Lighter, more regular, and less painful periods.
- Reduced Risk of Ovarian and Endometrial Cancers: Long-term use is associated with a decreased incidence of these cancers.
- Treatment of Polycystic Ovary Syndrome (PCOS) Symptoms: Can help regulate cycles and reduce androgenic effects in some women.

The clinical profile is understood and has been extensively documented. The drug's efficacy and safety are well-characterized, but newer agents may offer more favorable side-effect profiles or additional therapeutic benefits.

What are the Investment Considerations?

Investing in products like Ortho-Novum 2-21, especially the branded version, presents specific challenges and opportunities tied to its mature lifecycle and competitive environment.

Key Investment Considerations:

Market Share Erosion: The primary risk is continued loss of market share to generics and newer contraceptive modalities. This directly impacts revenue and profitability.
Price Compression: Generic competition will continue to exert downward pressure on pricing, limiting the revenue potential of any remaining branded sales.
Established Patient Base: Despite competition, a segment of the population may continue to use Ortho-Novum 2-21 due to physician recommendation, long-term tolerance, or perceived cost-effectiveness of a generic version.
Generic Manufacturing Opportunity: For companies specializing in generic pharmaceuticals, manufacturing and marketing generic Ortho-Novum 2-21 can represent a stable, albeit low-margin, revenue stream within a broader portfolio. The barrier to entry for generic production is relatively low, given the expiration of primary patents.
R&D Focus Shift: Pharmaceutical companies are typically focused on developing novel therapies and next-generation contraceptives with improved efficacy, safety, convenience, or unique benefits. Investment in the life cycle management of older products like Ortho-Novum 2-21 is usually minimal.
Brand Loyalty and Physician Preference: While declining, some residual brand loyalty and established physician prescribing habits can provide a baseline level of demand for the branded product.
Cost of Goods Sold (COGS): For generic manufacturers, efficient COGS is critical to maintaining profitability in a highly competitive market.

Investment Scenario Analysis:

For a branded product manufacturer like Johnson & Johnson (if still actively marketing it under the Ortho-Novum brand), continued investment would be limited. Focus would be on efficient supply chain management and minimal marketing to capture the residual demand from a loyal or mandated patient base. Profitability would be modest and declining.

For a generic manufacturer, Ortho-Novum 2-21 represents a product within a large and stable market segment. Investment would be focused on manufacturing efficiency, robust distribution channels, and competitive pricing strategies. Success depends on market share capture within the generic space and effective cost management.

For an investor looking at the pharmaceutical sector, Ortho-Novum 2-21 is not a growth asset. Investment in companies holding branded rights would be based on their ability to manage a mature portfolio, while investment in generic manufacturers would assess their overall generic drug strategy, operational efficiency, and ability to compete in a price-sensitive market.

Key Takeaways

Ortho-Novum 2-21's foundational patents have expired, allowing for generic competition.
The product faces intense competition from a wide range of newer oral contraceptives and alternative birth control methods.
Market dynamics are characterized by price erosion and declining market share for the branded product.
Investment opportunities lie primarily with generic manufacturers focused on efficient production and competitive pricing.
The branded product offers limited growth potential, with any remaining revenue derived from established patient use and physician preference.

Frequently Asked Questions

Are there any active patents that prevent generic Ortho-Novum 2-21 production? No, the primary composition of matter and method of use patents for the standard Ortho-Novum 2-21 formulation have expired. Generic manufacturers can produce the drug without infringing on these foundational patents.
What is the typical price difference between branded Ortho-Novum 2-21 and its generic versions? Generic versions of Ortho-Novum 2-21 are typically priced significantly lower than the branded product, often 50-80% less, depending on the manufacturer, insurance coverage, and pharmacy.
Does Ortho-Novum 2-21 offer any unique clinical advantages over newer contraceptives? Ortho-Novum 2-21 has a well-established efficacy and safety profile. However, newer contraceptives often offer advantages such as lower hormone doses, alternative progestins with potentially different side-effect profiles, or more convenient delivery systems (e.g., patches, rings, long-acting implants).
What is the expected market trajectory for Ortho-Novum 2-21 in the next five years? The market trajectory for Ortho-Novum 2-21 is expected to continue its decline in terms of market share and sales volume for the branded product, primarily due to ongoing generic competition and the increasing adoption of newer contraceptive technologies. Generic versions will likely maintain a stable, albeit competitive, market presence.
Who are the primary manufacturers of generic Ortho-Novum 2-21? Major generic pharmaceutical manufacturers such as Teva Pharmaceuticals, Aurobindo Pharma, Viatris (formerly Mylan), and AbbVie (through its acquisition of Allergan and Actavis) are among those that have produced or currently produce generic versions of Ortho-Novum 2-21.

Citations

[1] Ortho-Novum™ 2-21 product information. (n.d.). [Manufacturer's prescribing information for Ortho-Novum 2-21, typically available through FDA's Drugs@FDA database or manufacturer websites. Specific citations may vary based on the version accessed.]

[2] Trussell, J. (2011). Contraceptive efficacy. In R. H. Hatcher, J. T. G. Rivera, M. D. Geoghegan, W. E. Nelson, F. Policar, I. T. Polan, & S. V. Yacobson (Eds.), Contraceptive technology (20th ed., pp. 167–207). Ardent Media.

[3] U.S. Food & Drug Administration. (2020, December 16). Combined hormonal contraceptives. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/combined-hormonal-contraceptives-action-plan

ORTHO-NOVUM 2-21 Drug Patent Profile

Which patents cover Ortho-novum 2-21, and when can generic versions of Ortho-novum 2-21 launch?

AI Deep Research

Questions you can ask:

Summary for ORTHO-NOVUM 2-21

US Patents and Regulatory Information for ORTHO-NOVUM 2-21

ORTHO-NOVUM 2-21: Patent Landscape and Investment Fundamentals Analysis